Amgen (AMGN) : R.h. Dinel Investment Counsel scooped up 375 additional shares in Amgen during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 7, 2016. The investment management firm now holds a total of 22,400 shares of Amgen which is valued at $3,752,000.Amgen makes up approximately 4.23% of R.h. Dinel Investment Counsel’s portfolio.
Other Hedge Funds, Including , Exxonmobil Investment Management Inc Tx reduced its stake in AMGN by selling 3,370 shares or 1.73% in the most recent quarter. The Hedge Fund company now holds 191,083 shares of AMGN which is valued at $32,006,403. Amgen makes up approx 0.67% of Exxonmobil Investment Management Inc Tx’s portfolio.Washington Trust Bank reduced its stake in AMGN by selling 83 shares or 1.27% in the most recent quarter. The Hedge Fund company now holds 6,476 shares of AMGN which is valued at $1,083,046. Amgen makes up approx 0.26% of Washington Trust Bank’s portfolio.West Oak Capital boosted its stake in AMGN in the latest quarter, The investment management firm added 65 additional shares and now holds a total of 10,262 shares of Amgen which is valued at $1,716,217. Amgen makes up approx 1.19% of West Oak Capital’s portfolio.Eqis Capital Management boosted its stake in AMGN in the latest quarter, The investment management firm added 8,761 additional shares and now holds a total of 30,295 shares of Amgen which is valued at $5,066,536. Amgen makes up approx 0.32% of Eqis Capital Management’s portfolio.Cullinan Associates Inc reduced its stake in AMGN by selling 1,795 shares or 2.51% in the most recent quarter. The Hedge Fund company now holds 69,605 shares of AMGN which is valued at $11,640,740. Amgen makes up approx 1.00% of Cullinan Associates Inc’s portfolio.
Amgen opened for trading at $167.94 and hit $168.1499 on the upside on Friday, eventually ending the session at $167.5, with a gain of 0.36% or 0.6 points. The heightened volatility saw the trading volume jump to 16,79,823 shares. Company has a market cap of $125,350 M.
On the company’s financial health, Amgen reported $2.84 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.74. The company had revenue of $5688.00 million for the quarter, compared to analysts expectations of $5579.33 million. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 EPS.
Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.